Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
28.03. | Cyxone comments on the clinical collaboration in the UK | 5 | Cision News | ||
25.03. | Cyxone enters important research collaboration | 4 | Cision News | ||
05.03. | Cyxone's CEO gives a status update | 7 | Cision News | ||
17.01. | Cyxone identifies target protein for rabeximod | 6 | Cision News | ||
15.01. | Cyxone reaches important milestone regarding mechanism of action | 5 | Cision News | ||
11.12.23 | Nasdaq Stockholm AB: Last day of trading in paid subscription shares (BTA) of Cyxone AB (651/23) | 241 | GlobeNewswire | Trading in Cyxone AB paid subscription shares is to cease. The last trading day
is December 12, 2023.
Short name: CYXO BTA
---------------------------
ISIN code: SE0021020450
---------------------------
Orderbook... ► Artikel lesen | |
20.11.23 | Cyxone welcomes a renewed engagement by Professor Rikard Holmdahl as Scientific Advisor | 5 | Cision News | ||
07.11.23 | Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of Cyxone AB | 353 | GlobeNewswire | With effect from November 08, 2023, the subscription rights in Cyxone AB will
be traded on First North Growth Market. Trading will continue up until and
including November 16, 2023.
Instrument: ... ► Artikel lesen | |
01.11.23 | XFRA CAPITAL ADJUSTMENT INFORMATION - 01.11.2023 | 628 | Xetra Newsboard | Das Instrument 7RT FI0009006951 VALOE OYJ EQUITY wird ex Kapitalmassnahme gehandelt am 01.11.2023 The instrument 7RT FI0009006951 VALOE OYJ EQUITY is traded ex capital adjustment on 01.11.2023Das Instrument... ► Artikel lesen | |
27.10.23 | CYXONE: Interim Report 1 January to 30 September 2023 | 6 | Cision News |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 80,00 | -0,68 % | BioNTech: Alle Aktien verkaufen oder? | Richtig leiden müssen heute BioNTech-Aktionäre. In den Büchern steht für den Kurs nämlich ein Minus von rund zwei Prozent. Nur noch 81,45 EUR müssen nach diesem Abschlag für ein Wertpapier hingelegt... ► Artikel lesen | |
VALNEVA | 3,658 | -0,49 % | Valneva: Analyst sieht 105-Prozent-Chance | Valneva hat jüngst mit der Markteinführung neuer Produkte Schlagzeilen gemacht. Dies hat Analysten dazu veranlasst, die Aktie erneut zu bewerten. Finanztreff.de verrät, wie First Berlin Equity Research... ► Artikel lesen | |
NOVAVAX | 3,631 | -0,53 % | Novavax Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
AETERNA ZENTARIS | 1,820 | -1,62 % | Aeterna Zentaris Inc: Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris | TORONTO and EDMONTON, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) ("Ceapro") are pleased to announce... ► Artikel lesen | |
BAVARIAN NORDIC | 19,750 | -0,88 % | Resolutions of the Annual General Meeting 2024 of Bavarian Nordic A/S | COPENHAGEN, Denmark, April 16, 2024 - Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2023 was adopted. The Board of Directors'... ► Artikel lesen | |
BELLEROPHON THERAPEUTICS | 0,001 | -100,00 % | Delisting of Securities of SmileDirectClub, Inc.; Bellerophon Therapeutics, Inc.; Elys Game Technology; Athersys, Inc.; Borqs Technologies; ContraFect Corporation; CohBar, Inc.; AgileThought, Inc.; Fat Projects Acquisition; Evelo Biosciences ... | NEW YORK, Dec. 26, 2023 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of SmileDirectClub, Inc. SmileDirectClub, Inc.'s securities were suspended on... ► Artikel lesen | |
PHIO PHARMACEUTICALS | 0,649 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID) | MARLBOROUGH, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL siRNA gene silencing technology is... ► Artikel lesen | |
ORAGENICS | 1,160 | 0,00 % | ORAGENICS INC - 8-K, Current Report | ||
LEXICON PHARMACEUTICALS | 1,550 | +1,97 % | Lexicon Pharmaceuticals, Inc.: Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo | THE WOODLANDS, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that four data presentations related to sotagliflozin, an inhibitor of two sodium... ► Artikel lesen | |
CSTONE PHARMACEUTICALS | 0,104 | 0,00 % | CSTONE PHARMA-B (02616): PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF THE NEW MEMORANDUM AND ARTICLES OF ... | ||
OUTLOOK THERAPEUTICS | 8,435 | +4,65 % | Outlook Therapeutics, Inc.: Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million | ||
NANOSPHERE HEALTH SCIENCES | 0,009 | 0,00 % | The Morning After: 'Nanosphere' paint could reduce a plane's CO2 emissions | ||
GENSCRIPT BIOTECH | 1,380 | +4,55 % | China's Genscript hits 3-year low after unit's downbeat Q1 sales for blood cancer therapy | ||
VERVE THERAPEUTICS | 6,745 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
LEAP THERAPEUTICS | 2,860 | +2,14 % | Leap Therapeutics To Sell $40 Mln Of Shares In Private Placement; Stock Up Over 14% |